Revolutionize Diagnostics for Future Generations
Management
Dr. Fabian Mohr
CO-FOUNDER
Managing Director
Fabian has 12+ years professional experience in cancer research, software development, strategy consulting and venture capital. He was holding several board mandates of life science companies prior joining LIMAA. He is responsible for business development, licensing, general management and overall strategy in the company.
Dr. Dr. René Hägerling
CO-FOUNDER
Head of R&D
René has more than a decade experience in developing and adapting technology for 3D histology. As a chemist and medical doctor, he is responsible for the development of scientific breakthrough technologies in the company. He further is a group leader at Charité University Hospital Berlin where he focusses on 3D spatial histology.
Camila Tomikawa, MD
CO-FOUNDER
Head of Pathology & Medical Affairs
Camila is a pathologist with a medical informatician MSc and has been working with several digital pathology startups as a Medical Advisor to build scalable and efficient digital pathology workflows and clinical decision support systems. As an expert in the field she advises on LIMAAs strategies for clinical validation and integration of products.
Nadine Hülsemann
Head of Production
Nadine is a skilled biologist with a strong background in the production of in vitro diagnostic (IVD) products. As Head of Production at LIMAA Technologies, she focuses on enhancing manufacturing efficiency through process optimization and automation. Her expertise bridges scientific innovation and operational strategy to ensure the manufacturing of high-quality IVD solutions.
Mélanie Guenter
CO-FOUNDER
Head of Operations & IT
Mélanie brings over 20 years of experience in the healthcare and biotech industry, where she has built a strong track record in optimizing operations, driving digital transformation, and ensuring compliance. At LIMAA Technologies, she oversees IT, data privacy, software development, and quality management while continuously refining processes to enhance efficiency and scalability. With a background in business informatics and biotechnology, she bridges technology and regulation to create innovative, secure digital solutions for healthcare.
Advisors
Prof. Dr. Bruno Märkl
DIRECTOR PATHOLOGY, UK AUGSBURG
Prof. Märkl is a highly experienced pathologist incorporating several facets of digital pathology in his institute. He serves as a medical advisor for LIMAA Technologies.
Dr. Georg Kox
SERIAL ENTREPRENEUR,
EX-VC
Dr. Kox has 25+ years professional experience in the healthcare industry in several different roles and a succesfull exit of a diagnostics company. He serves as a business advisor.
History of the Company
LIMAA Technologies (LIght-sheet Microscopy and Automated Analysis) is a spin-off from the working group of Dr. Dr. René Hägerling from Charité - University Hospital in Berlin.
René, with over a decade of experience in three-dimensional tissue analysis, initially focused on embryonic vascular development when faced with limitations in standard two-dimensional histology methods. He played a pivotal role in testing light-sheet microscopes from German startups and companies, pioneering spatial visualization of the vascular system.
During the 2014 Lindau Nobel Laureate Meeting, René met Dr. Fabian Mohr, who had transitioned from oncology research to strategy consulting and venture capital. Their collaboration began in 2017, aiming to apply light-sheet microscopy to clinical diagnostics. They garnered interest from private health insurers, particularly for diagnosing lymphedema and lipoedema, where clear tests were lacking.
After earning degrees in Chemistry, Medicine, and a PhD in Biology and Imaging, René left the Max Planck Institute for Molecular Biomedicine in Münster for a residency at the Charité - University Hospital in Berlin. There, he continued developing light-sheet imaging-based diagnostics and, in 2019, entered the Berlin Institute of Health Digital Health Accelerator with Fabian. They evolved their concept into an automated platform for histopathology on entire tissue biopsies, departing from glass slide-based analyses.
In 2020, René and Fabian collaborated with Prof. Bruno Märkl from the University Hospital in Augsburg for a clinical feasibility study, yielding promising pilot data. In 2021, they secured EXIST funding to transform their scientific and clinical findings into products, marking the beginning of LIMAA Technologies. Subsequent support came from Prof. David Horst at Charité's Institute of Pathology, a European Research Council grant, and the establishment of LIMAA Technologies GmbH in 2022.
Get in Touch for More Information
If you are interested in learning more about our team, our technology and our vision feel free to reach out to us.